Cymbalta Tapering Guide
duloxetine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Duloxetine is an SNRI approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. It is known for a difficult discontinuation syndrome.
20mg, 30mg, 60mg, 120mg
Delayed-release capsules: 20mg, 30mg, 60mg
Category C (risk cannot be ruled out)
Mechanism of Action
Potent inhibitor of both serotonin and norepinephrine reuptake (SNRI). Unlike venlafaxine, it inhibits both transporters at standard therapeutic doses. Weak inhibitor of dopamine reuptake.
Taper Notes
Discontinuation syndrome is among the most severe of any antidepressant. Capsules contain enteric-coated pellets — bead counting is feasible but pellets are small. Compounded liquid suspension is a useful alternative for fine titration.
Maudsley Deprescribing Guidance
Hyperbolic reductions (~10% per step) using bead counting from delayed-release capsules; do not crush enteric-coated pellets. Compounding pharmacies can prepare oral suspension for sub-mg increments.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Reduce by ~25% using available capsule strengths. Withdrawal symptoms often emerge early; pre-empt with patient education. |
| Middle reductions | 6-8 weeks | Transition to pellet counting or compounded suspension for proportional reductions. Do not crush enteric-coated pellets. |
| Lower dose reductions | 8-10 weeks | Compounded duloxetine suspension permits sub-mg increments not achievable with available capsule strengths. |
| Final reductions | 8-12 weeks | Very gradual hyperbolic reductions essential. Extend hold periods to 4+ weeks per step if symptoms emerge. |
Withdrawal Timeline
1-2 days after dose reduction
3-5 days
2-4 weeks for most symptoms
Brain zaps, nausea, and cognitive fog may persist 2-4 months. Cymbalta discontinuation lawsuits have documented the severity of its withdrawal.
Clinical Pearls
Practical considerations for clinicians supervising Cymbalta tapers.
- 1Pellet counting from delayed-release capsules permits sub-strength dosing. Enteric coating must remain intact — do not crush or chew the pellets.
- 2Compounded duloxetine suspension is available through many compounding pharmacies and is the preferred tool for sub-mg increments below 20 mg.
- 3Patients commonly report a distinctive "whooshing" cranial sensation during duloxetine discontinuation, distinct from classic SSRI brain zaps; reassure that this is time-limited.
- 4The 20 mg capsule strength is essential for tapering but is sometimes not stocked; coordinate with the dispensing pharmacy ahead of dose reductions.
- 5Encourage daily symptom tracking. Duloxetine withdrawal severity is well-documented and patient data sharpens taper-pacing decisions.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (serotonin syndrome risk)
- CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) substantially increase duloxetine levels — avoid combination
- CYP2D6 inhibitors increase duloxetine levels
Food Interactions
- Food delays absorption but does not significantly change total exposure
- Avoid heavy alcohol use (hepatotoxicity risk)
Contraindications
- MAOIs within 14 days
- Uncontrolled narrow-angle glaucoma
- Severe hepatic impairment
Toxicity
Serotonin syndrome with serotonergic combinations. Hepatotoxicity rare but reported. Severe discontinuation syndrome. Avoid in hepatic impairment and heavy alcohol use.
Pharmacokinetics
ADME Profile
Well absorbed, but enteric coating delays absorption (Tmax 6 hours). Bioavailability ~50% (range 32–80%). Food delays Tmax by 6–10 hours and reduces AUC slightly.
~1640 L (~23 L/kg)
Extensively metabolized hepatically via CYP1A2 (primary) and CYP2D6. Numerous metabolites, none pharmacologically active.
Renal (~70% as metabolites, <1% unchanged) and fecal (~20%).
>90% (primarily albumin and alpha-1-acid glycoprotein)
~114 L/hr (apparent oral clearance)
Build Cymbalta taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds